National Institutes of Health Consensus Development Conference statement: hydroxyurea treatment for sickle cell disease.
Brawley
Otis W
OW
American Cancer Society, 250 Williams Street, Atlanta, GA 30303, USA.
Cornelius
Llewellyn J
LJ
Edwards
Linda R
LR
Gamble
Vanessa Northington
VN
Green
Bettye L
BL
Inturrisi
Charles
C
James
Andra H
AH
Laraque
Danielle
D
Mendez
Magda
M
Montoya
Carolyn J
CJ
Pollock
Brad H
BH
Robinson
Lawrence
L
Scholnik
Aaron P
AP
Schori
Melissa
M
D000293:Adolescent; D000328:Adult; D000755:Anemia, Sickle Cell / Q000188:drug therapy*; D000986:Antisickling Agents / Q000009:adverse effects / Q000627:therapeutic use*; D035843:Biomedical Research; D002648:Child; D003695:Delivery of Health Care / Q000592:standards; D006297:Health Services Accessibility; D006801:Humans; D006918:Hydroxyurea / Q000009:adverse effects / Q000627:therapeutic use*; D007223:Infant; D010146:Pain / Q000517:prevention & control; D010353:Patient Education as Topic / Q000592:standards; D010817:Physician-Patient Relations
D000986:Antisickling Agents; D006918:Hydroxyurea